<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2018 [PPXK5GW761L0VLJ1MPZR]. www.edgarsuite.com -->
<HEAD>
<TITLE>
 &nbsp;</TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><P align=center style='font:18pt Times New Roman;margin-top:2.25pt;margin-bottom:0pt'><FONT style=font-size:18pt><B>UNITED STATES</B></FONT></P>
<P align=center style='font:18pt Times New Roman;margin:0'><FONT style=font-size:18pt><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P>
<P align=center style='font:12pt Times New Roman;margin:0'><B>Washington, D.C. 20549 </B></P>
<P style='font:4.5pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:12pt Times New Roman;margin-top:0pt;margin-bottom:1.5pt'>&#160;</P>
<P align=center style='font:18pt Times New Roman;margin-top:4.5pt;margin-bottom:0pt'><FONT style=font-size:18pt><B>FORM 8-K </B></FONT></P>
<P style='font:12pt Times New Roman;margin-top:0pt;margin-bottom:1.5pt'>&nbsp;</P>
<P align=center style='font:12pt Times New Roman;margin-top:12pt;margin-bottom:0pt'><B>CURRENT REPORT</B></P>
<P align=center style='font:12pt Times New Roman;margin:0'><B>Pursuant to Section 13 or 15(d)</B></P>
<P align=center style='font:12pt Times New Roman;margin:0'><B>Of the Securities Exchange Act of 1934</B></P>
<P align=center style='font:12pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:12pt Times New Roman;margin:0'><B>Date of Report (Date of earliest event reported): September 18, 2018</B></P>
<P align=center style='font:20pt Times New Roman;margin-top:18pt;margin-bottom:0pt'><B>MOUNT TAM BIOTECHNOLOGIES, INC. </B></P>
<P align=center style='font:7.5pt Times New Roman;margin:0'><FONT style=font-size:7.5pt><B>(Exact name of registrant as specified in its charter) </B></FONT></P>
<P style='font:4.5pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE align=center style=border-collapse:collapse;width:100%><TR><TD valign=middle><P style='font:12pt Times New Roman;margin:0'>&#160;</P>
</TD><TD valign=bottom><P style='font:12pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=middle><P style='font:12pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top><P align=center style='font:10pt Times New Roman;margin:0'><FONT style=font-size:10pt><B>NEVADA</B></FONT></P>
</TD><TD valign=bottom><P align=center style='font:10pt Times New Roman;margin:0'><B>333-192060</B></P>
</TD><TD valign=top><P align=center style='font:10pt Times New Roman;margin:0'><FONT style=font-size:10pt><B>45-3797537</B></FONT></P>
</TD></TR>
<TR style=height:3.7pt><TD valign=middle><P align=center style='font:7.5pt Times New Roman;margin:0'><FONT style=font-size:7.5pt><B>(State or other jurisdiction&#160;of</B></FONT></P>
<P align=center style='font:7.5pt Times New Roman;margin-top:0pt;margin-bottom:0.75pt'><FONT style=font-size:7.5pt><B>incorporation or organization)</B></FONT></P>
</TD><TD valign=middle><P align=center style='font:7.5pt Times New Roman;margin:0'><FONT style=font-size:7.5pt><B>(Commission File Number)</B></FONT></P>
</TD><TD valign=middle><P align=center style='font:7.5pt Times New Roman;margin:0'><FONT style=font-size:7.5pt><B>(I.R.S. Employer</B></FONT></P>
<P align=center style='font:7.5pt Times New Roman;margin-top:0pt;margin-bottom:0.75pt'><FONT style=font-size:7.5pt><B>Identification Number)</B></FONT></P>
</TD></TR>
</TABLE>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'><B>7250 Redwood Boulevard, Suite 300</B></FONT></P>
<P align=center style='font:10pt Times New Roman;margin:0'><FONT style='font-size:10pt;border-bottom:1px solid #000000'><B>Novato, California &nbsp;94925</B></FONT><FONT style=font-size:10pt><B> </B></FONT></P>
<P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'><B>(425) 214-4079</B></FONT></P>
<P align=center style='font:10pt Times New Roman;margin:0'><FONT style=font-size:10pt><B> </B></FONT>&nbsp;</P>
<P align=center style='font:7.5pt Times New Roman;margin:0'><FONT style=font-size:7.5pt><B>(Address, including zip code, and telephone number, </B></FONT></P>
<P align=center style='font:7.5pt Times New Roman;margin:0'><FONT style=font-size:7.5pt><B>including area code, of registrant&#8217;s principal executive offices) </B></FONT></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&#160;</P>
<P align=center style='font:10pt Times New Roman;margin:0'>N/A</P>
<P align=center style='font:7.5pt Times New Roman;margin:0'><B>(Former name or former address, if changed since last report)</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&#160;</P>
<P style='font:10pt Times New Roman;margin:0'>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE align=center style=border-collapse:collapse;width:100%><TR><TD valign=top><P style='font:10pt Times New Roman;margin:0'><FONT style=font-family:Wingdings>&#168;</FONT></P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE align=center style=border-collapse:collapse;width:100%><TR><TD valign=top><P style='font:10pt Times New Roman;margin:0'><FONT style=font-family:Wingdings>&#168;</FONT></P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE align=center style=border-collapse:collapse;width:100%><TR><TD valign=top><P style='font:10pt Times New Roman;margin:0'><FONT style=font-family:Wingdings>&#168;</FONT></P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE align=center style=border-collapse:collapse;width:100%><TR><TD valign=top><P style='font:10pt Times New Roman;margin:0'><FONT style=font-family:Wingdings>&#168;</FONT></P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin-top:0pt;margin-bottom:10pt;background-color:#FFFFFF'>&nbsp;</P>
<P style='font:10pt inherit;margin-top:0pt;margin-bottom:10pt;color:#212121;background-color:#FFFFFF'><FONT style='font-family:Times New Roman;color:#000000'>&#160;</FONT><FONT style='font-family:Times New Roman'>Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</FONT></P>
<P style='font:10pt inherit;margin:0;color:#212121;background-color:#FFFFFF'><FONT style='font-family:Times New Roman;color:#000000'>Emerging growth company &nbsp;&nbsp;&#9744;</FONT></P>
<HR style='border:0;height:0;width:0;margin:15pt 0 0 0'><A name=_iDocIDField6c1b6015-351d-433f-b839-0f01 /><P align=right style='font:10pt Times New Roman;margin:0'>1<FONT style=font-size:10pt> </FONT></P>
<HR style='page-break-after:always;border:0;height:3.75pt;background-color:#919191;margin:15pt 0'><P style=line-height:0;margin:0></P>
<P style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#9744;</P>
<P style='font:8pt Times New Roman;margin:0'><FONT style=font-size:8pt>&#160; </FONT></P>
<HR style='page-break-after:always;border:0;height:3.75pt;background-color:#919191;margin:15pt 0'><P style=line-height:0;margin:0></P>
<P style='font:10pt Times New Roman;margin:0;color:#000000'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0pt'><FONT style=background-color:#FFFFFF><B>Item 1.01</B></FONT></KBD><KBD style=margin-left:72pt></KBD><FONT style=background-color:#FFFFFF><B>Entry into a Material Definitive Agreement.</B></FONT>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0pt'><FONT style=background-color:#FFFFFF><B>Item&#160;2.01 </B></FONT></KBD><KBD style=margin-left:72pt></KBD><FONT style=background-color:#FFFFFF><B>Completion of Acquisition or Disposition of Assets.</B></FONT>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;color:#000000;background-color:#FFFFFF'><FONT style=color:#212121;background-color:#FFFFFF><I>Sale of Wholly-Owned Subsidiary</I></FONT></P>
<P style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:36pt;color:#000000;background-color:#FFFFFF'>On October 18, 2018, Mount Tam Biotechnologies, Inc., a Nevada corporation (the &#8220;Company&#8221;), and its wholly-owned subsidiary, Mount Tam Biotechnologies, Inc., a Delaware corporation (the &#8220;Subsidiary&#8221;) entered into a stock purchase agreement (the &#8220;SPA&#8221;) with ARJ Consulting, LLC, a New York limited liability company (the &#8220;Buyer&#8221;), pursuant to which the Company sold 100% of the capital stock in and of Subsidiary to the Buyer (the &#8220;Sale Transaction&#8221;). Prior to the Sale Transaction, the Company caused Subsidiary to transfer certain assets and a key license that Subsidiary was holding to another wholly-owned subsidiary of the Company, Mount Tam Therapeutics, Inc., a Delaware corporation. At the time of the Sale Transaction Subsidiary possessed certain Net Operating Losses and tax credits. Pursuant to the terms of the SPA, the Buyer purchased Subsidiary for a purchase price of $410,000. </P>
<P style='font:10pt Times New Roman;margin:0;text-indent:36pt;color:#000000;background-color:#FFFFFF'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:36pt;color:#000000;background-color:#FFFFFF'>The foregoing description of the sale of Subsidiary does not purport to be complete and is qualified in its entirety by reference to the actual terms and conditions of the SPA, a copy of which is being filed as Exhibit&#160;10.1 hereto, and is incorporated herein by reference.</P>
<P style='font:10pt Times New Roman;margin:0;color:#000000;background-color:#FFFFFF'>&#160;</P>
<P style='font:10pt Times New Roman;margin:0'><B>Item 9.01</B> <B>Financial Statements and Exhibits.</B></P>
<P style='font:10pt Times New Roman;margin:0'><A name=co_internalToc_EXL_1 />&#160;</P>
<P style='font:10pt Times New Roman;margin:0'>(d) Exhibits</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE align=center style=border-collapse:collapse;margin-left:4.65pt><TR style=height:10.8pt><TD valign=middle style='width:63pt;padding-top:1.8pt;padding-right:1.8pt;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Exhibit No.</P>
</TD><TD valign=middle style=width:29pt;padding-top:1.8pt;padding-right:1.8pt><P style='font:10pt Times New Roman;margin:0'>&#160;</P>
</TD><TD valign=middle style='width:305pt;padding-top:1.8pt;padding-right:1.8pt;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Description</P>
</TD></TR>
<TR style=height:10.8pt><TD valign=middle style=width:63pt;padding-top:1.8pt;padding-right:1.8pt><P style='font:10pt Times New Roman;margin:0'>10.1</P>
</TD><TD valign=middle style=width:29pt;padding-top:1.8pt;padding-right:1.8pt><P style='font:10pt Times New Roman;margin:0'>&#160;</P>
</TD><TD valign=middle style=width:305pt;padding-top:1.8pt;padding-right:1.8pt><P style='font:10pt Times New Roman;margin:0'><FONT style=color:#212121;background-color:#FFFFFF>Stock Purchase Agreement</FONT></P>
</TD></TR>
<TR style=height:10.8pt><TD valign=middle style=width:63pt;padding-top:1.8pt;padding-right:1.8pt><P style='font:10pt Times New Roman;margin:0;color:#000000'>&nbsp;</P>
</TD><TD valign=middle style=width:29pt;padding-top:1.8pt;padding-right:1.8pt><P style='font:10pt Times New Roman;margin:0;color:#000000'>&nbsp;</P>
</TD><TD valign=middle style=width:305pt;padding-top:1.8pt;padding-right:1.8pt><P style='font:10pt Times New Roman;margin:0;color:#212121'>&nbsp;</P>
</TD></TR>
</TABLE>
<HR style='page-break-after:always;border:0;height:3.75pt;background-color:#919191;margin:15pt 0'><P style=line-height:0;margin:0></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SIGNATURES</B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:36pt'>Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><B>MOUNT TAM BIOTECHNOLOGIES, INC.</B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE align=center style=border-collapse:collapse;width:100%><TR><TD colspan=2 valign=top><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top><P style='font:10pt Times New Roman;margin:0'>Date:&#160;&#160;&#160;</P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>October 22, 2018</P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top><P style='font:10pt Times New Roman;margin:0'>By: </P>
</TD><TD valign=top style=white-space:nowrap><P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>/s/ <I>Richard Marshak</I></FONT></P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top><P style='font:10pt Times New Roman;margin:0'>Name: </P>
</TD><TD valign=bottom style=white-space:nowrap><P style='font:10pt Times New Roman;margin:0'>Richard Marshak</P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top><P style='font:10pt Times New Roman;margin:0'>Title:</P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>Chief Executive Officer</P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:11pt Calibri;margin:0'>&nbsp;</P>
</DIV>
</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "mntm_8k.htm", "description": "8-K", "secsgml_size_bytes": 15501}]
{"company-data": {"conformed-name": "Mount TAM Biotechnologies, Inc.", "cik": "0001589361", "assigned-sic": "2100", "irs-number": "453797537", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "333-192060", "film-number": "181133782"}, "business-address": {"street1": "7250 REDWOOD BLVD, SUITE 300", "city": "NOVATO", "state": "CA", "zip": "94945", "phone": "(425) 214-4079"}, "mail-address": {"street1": "7250 REDWOOD BLVD, SUITE 300", "city": "NOVATO", "state": "CA", "zip": "94945"}, "former-company": [{"former-conformed-name": "TabacaleraYsidron, Inc.", "date-changed": "20140206"}, {"former-conformed-name": "TABACALERAYSIDRON INC", "date-changed": "20140206"}, {"former-conformed-name": "TABACALERA YSIDRON INC", "date-changed": "20131016"}]}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
Of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 18, 2018
MOUNT TAM BIOTECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
NEVADA
333-192060
45-3797537
(State or other jurisdiction of
incorporation or organization)
(Commission File Number)
(I.R.S. Employer
Identification Number)
7250 Redwood Boulevard, Suite 300
Novato, California  94925
(425) 214-4079
(Address, including zip code, and telephone number,
including area code, of registrant's principal executive offices)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company   ☐
1
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Item 1.01
Entry into a Material Definitive Agreement.
Item 2.01
Completion of Acquisition or Disposition of Assets.
Sale of Wholly-Owned Subsidiary
On October 18, 2018, Mount Tam Biotechnologies, Inc., a Nevada corporation (the "Company"), and its wholly-owned subsidiary, Mount Tam Biotechnologies, Inc., a Delaware corporation (the "Subsidiary") entered into a stock purchase agreement (the "SPA") with ARJ Consulting, LLC, a New York limited liability company (the "Buyer"), pursuant to which the Company sold 100% of the capital stock in and of Subsidiary to the Buyer (the "Sale Transaction"). Prior to the Sale Transaction, the Company caused Subsidiary to transfer certain assets and a key license that Subsidiary was holding to another wholly-owned subsidiary of the Company, Mount Tam Therapeutics, Inc., a Delaware corporation. At the time of the Sale Transaction Subsidiary possessed certain Net Operating Losses and tax credits. Pursuant to the terms of the SPA, the Buyer purchased Subsidiary for a purchase price of $410,000.
The foregoing description of the sale of Subsidiary does not purport to be complete and is qualified in its entirety by reference to the actual terms and conditions of the SPA, a copy of which is being filed as Exhibit 10.1 hereto, and is incorporated herein by reference.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
10.1
Stock Purchase Agreement
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MOUNT TAM BIOTECHNOLOGIES, INC.
Date:
October 22, 2018
By:
/s/
Richard Marshak
Name:
Richard Marshak
Title:
Chief Executive Officer